Suche Forschungsprojekt
Weitere Suchoptionen
118 Ergebnis(se)
Abgeschlossene Forschungsprojekte = 
Förderung durch ein IRDiRC-Mitglied = 
ERN-Mitglied = 
Forschungsprojekt(e)
BELGIEN
HAINAUT
GOSSELIES
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort - BE
Institut de Pathologie et de Génétique
Département de Génétique Clinique - Institut de Pathologie et de Génétique (IPG)
BELGIEN
VLAAMS BRABANT
LEUVEN
Longitudinal Measurement of Synaptic Density to Monitor Progression of Huntington's Disease
UZ Leuven - Campus Gasthuisberg
Huntington Clinic
BELGIEN
VLAAMS BRABANT
LEUVEN
Direct Quantitative Comparison Between [11C]UCB-J and [18F]SynVest-1 PET as Markers for Synaptic Density in Premanifest and Manifest Huntington's Disease
UZ Leuven - Campus Gasthuisberg
Huntington Clinic
DEUTSCHLAND
Baden-Württemberg
ULM
REPETOMICS: Genomische Instabilität von erweiterten DNA-Wiederholungen bei Chorea Huntington, Amyotropher Lateralsklerose und Frontotemporaler Demenz
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
DEUTSCHLAND
Bayern
NEUHERBERG
PolyQure: Ursächliche Behandlung von Polyglutamin-Erkrankungen durch Inhibition von TRMT2A - Hochdurchsatz- und strukturbiologische Verfahren
Helmholtz Zentrum München
Institut für Strukturbiologie - AG Niessing
DEUTSCHLAND
Nordrhein-Westfalen
BOCHUM
TreatPolyQ: Allel-spezifische Reduzierung der mutierten Polyglutamin-Proteine zur Behandlung der Huntington-Krankheit, spinozerebellären Ataxie Typ 3 und spinozerebellären Ataxie Typ 7 (Koordinator)
Ruhr-Universität Bochum
Humangenetik Bochum
FRANKREICH
AUVERGNE-RHONE-ALPES
LA TRONCHE
Axonal transport and neuronal maturation: consequences for synaptic function and neuronal connections in normal situation and in Huntington's disease
Grenoble-Institut des Neurosciences (GIN)
Grenoble-Institut des Neurosciences
FRANKREICH
AUVERGNE-RHONE-ALPES
SAINT-MARTIN-D'HČRES
FUELING-TRANSPORT: Untangling the role of the huntingtin protein in health and in Huntington's disease
Université Grenoble Alpes
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Neuroprotective role of CYP46A1 in Huntington’s disease using gene transfer therapy in brain
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
VILLENEUVE D'ASCQ
Dyadic dynamics of couples in Huntington disease
Université Lille 3
Equipe Dynamique Emotionnelle et Pathologies
FRANKREICH
ILE-DE-FRANCE
FONTENAY-AUX-ROSES
Innovative Imaging and BIO Cognitive Markers to Predict the Progression of Huntington's Disease
CEA - Commissariat ŕ l'Energie Atomique
Laboratoire des Maladies Neurodégénératives
FRANKREICH
ILE-DE-FRANCE
PARIS
Efficient Gene and Sterol regulations by gene transfer for striatal protection in Huntington's Disease
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpętričre
APHP.Sorbonne Université, Hôpital de la Pitié-Salpętričre
FRANKREICH
ILE-DE-FRANCE
PARIS
Development of therapeutic strategies for human degenerative diseases
Centre Paul Broca
Biologie et pathologie du neurone
FRANKREICH
ILE-DE-FRANCE
PARIS
Cell-Type-Specific Gene and Sterol Profiling following CYP46A1 gene therapy in Huntington disease
Université Pierre et Marie Curie - Paris 6 - UPMC
Neuroscience Paris Seine (CNRS UMR8246/Inserm U1130/UMPC UMCR18)
FRANKREICH
ILE-DE-FRANCE
PARIS
Brain response to Huntington's disease: role of small vesicles
Université Pierre et Marie Curie - Paris 6 - UPMC
Adaptation Biologique et Vieillissement
FRANKREICH
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
REPETOMICS: Genomic Instability of Expanded Repeats in HD and ALS/FTD - FR
Institut de Neurosciences de la Timone
UMR7289
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Role of the Coiled-coil structure of the Huntingtin protein in the intercellular propagation of polyQ aggregates and in the progression of the disease
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
BOLOGNA
Enroll-HD - A Prospective Registry Study in a Global HD Cohort - IT
Universitŕ di Bologna - Istituto di Clinica Neurologica
Laboratorio di Neurogenetica
ITALIEN
LAZIO
ROMA
Alteration in cortical parvalbuminergic System in murine model of Huntington's disease: pharmacological effect of phosphodiesterase type 4 (PDE4) inhibition
Fondazione EBRI
Istituto di Neurobiologia e Medicina Molecolare
ITALIEN
LAZIO
ROMA
Analysis of apoptosis in neurodegenerative diseases by apaf1 conditional mutagenesis (terminated)
Universitŕ degli Studi di Roma Tor Vergata
Laboratorio di Genetica delle Popolazioni
ITALIEN
LOMBARDIA
MILANO
Innovative Therapeutic Strategy Targeting Neurons With Cholesterol in Huntington Disease: From Preclinical Studies to Clinical Trial Readiness
Fondazione IRCCS Istituto Neurologico "Carlo Besta"
U.O.C. Genetica Medica e Neurogenetica
ITALIEN
LOMBARDIA
MILANO
Targeting neurons with cholesterol. How can it change the future of Huntington Disease patients
Universitŕ degli Studi di Milano - Scienze Biomolecolari e Biotecnologiche
Dipartimento di Bioscienze
KANADA
Alberta
EDMONTON
Therapeutic role of ganglioside GM1 in Huntington's disease
University of Alberta
Department of Pharmacology
KANADA
Colombie-Britannique
VANCOUVER
Novel approaches to modulate key targets in the pathogenesis of Huntington Disease
Centre for Molecular Medicine and Therapeutics
KANADA
Colombie-Britannique
VANCOUVER
Altered balance of synaptic/extrasynaptic NMDA receptor signaling in Huntington disease
University of British Columbia
Centre for Huntington Disease- UBC Hospital
KANADA
Ontario
HAMILTON
Elucidating the Protective Mechanism of Phospho-N17 Huntingtin in Huntington's disease
McMaster University
Biochemistry and Biomedical Sciences
KANADA
Ontario
HAMILTON
Defective DNA Damage Repair and Aberrant PARylation as a Mechanism of Mutant Huntingtin in Huntington's Disease
McMaster University
Biochemistry and Biomedical Sciences
KANADA
Ontario
TORONTO
DNA repair proteins as modifiers of CAG repeat instability in Huntington's disease
The Hospital for Sick Children
Genetics and Genome Biology
KANADA
Québec
QUÉBEC
Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment
CHUQ - (CHUL) Centre hospitalier de l'Université Laval
Axe Neuosciences, CHUL
NIEDERLANDE
Zuid-Holland
LEIDEN
Investigating cell-specific pathology in Huntington's disease and spinocerebellar ataxia iPSC-derived brain assembloids before and after treatment with targeted antisense oligonucleotides
LUMC - Leids Universitair Medisch Centrum
PORTUGAL
CENTRO
COIMBRA
Analysis of transcription deregulation in brain and peripheral Huntington disease models - influence of modulating histone deacetylases.
Universidade de Coimbra - Centro de Neurocięncias e Biologia Celular
Grupo de Disfunçăo Mitocondrial e Morte Celular
SCHWEDEN
Region Skĺne
LUND
BAGADILICO: Hypothalamic changes and biomarkers in Huntington's disease
Lunds Universitet
Department of Experimental Medical Science
SCHWEDEN
Region Skĺne
LUND
Immune response in Huntington's disease and delineation of its importance for disease pathogenesis and biomarkers
Lunds Universitet
Department of Experimental Medical Science
SCHWEDEN
Region Stockholm
SOLNA
The functional organisation of the brain
Karolinska Institutet
Department of Clinical Neuroscience (CNS)
SCHWEIZ
Suisse Alémanique
ZÜRICH
Multinational research projects on Health and Social Care for Neurodegenerative Diseases DOMINO-HD (HESOCARE-329-017)
Universitätsspital Zürich
Klinik für Neurologie
SCHWEIZ
Suisse Romande
LAUSANNE
Toward gene repair for Huntington's disease
Centre Hospitalier Universitaire Vaudois CHUV
Laboratoire des neurothérapies et neuromodulation
SPANIEN
Cataluńa
BARCELONA
Biological-guided development and validation of specific cognitive assessment instruments in Huntington's disease
IIB Sant Pau - Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
SPANIEN
Cataluńa
BARCELONA
Gliotransmitters and Cannabinoid Receptors at the hub of cognitive and synaptic plasticity impairments in Huntington's disease
Universitat de Barcelona. Campus de Medicina - Clínic August Pi i Sunyer
Departamento de Biología Celular, Inmunología y Neurociencias
SPANIEN
Comunidad Valenciana
VALENCIA
Modulating the activity of genes controlling fat metabolism as a therapeutic strategy in Huntington disease
Hospital Universitario y Politécnico La Fe
Fundación para la Investigación del Hospital Universitari La Fe
SPANIEN
Madrid
MADRID
Gliotransmitters and Cannabinoid Receptors at the hub of cognitive and synaptic plasticity impairments in Huntington's disease
Instituto Cajal (CSIC)
Laboratorio de redes neuro-gliales
SPANIEN
Madrid
MADRID
Gliotransmitters and Cannabinoid Receptors at the hub of cognitive and synaptic plasticity impairments in Huntington's disease
Universidad Complutense de Madrid. Facultad de Medicina
Departamento de Bioquímica y Biología Molecular (Medicina)
TSCHECHISCHE REPUBLIK
Capital City Prague
PRAHA 2
Markers of mitochondrial dysfunction in presymptomatic and early stages of Huntington's disease
Vseobecna fakultni nemocnice a 1. lekarska fakulta UK
Neurologicka klinika
VEREINIGTE STAATEN
Maryland
BETHESDA
Developing inhibitors for PIP4Kgamma for Huntington's disease
National Center for Advancing Translational Sciences (NCATS-NIH)
Chemistry Technologies
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Investigating cd47-sirpa as novel protective signals during cns synaptic pruning
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Nanocarriers designed to deliver nucleic acids to brain
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Epigenetic pathology and therapy in huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Extrinsic mechanisms governing injury-induced axon degeneration
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Identification of gpr52 antagonists as potential treatments for huntington disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Identification of small molecules that decrease the activity of the huntingtin gene promoter for the potential treatment of huntington disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Identification of small molecules that increase activity of the huntingtin antisense promoter for the potential treatment of huntington disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Quantitative systems pharmacology approach to identify cytoprotective agents and pathways for huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Using a disease-affected cell to synthesize its own drug
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Cortical pathophysiology in mouse models of huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Cortico-basal ganglia connectivity in a non-human primate model of huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Early detection of huntington's disease: longitudinal analysis of basal ganglia and cortical thickness
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Genetic correction of mutant huntingtin in vivo
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Huntington's disease: a novel developmental oligodendrogliopathy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Identifying factors regulating medium spiny neuron differentiation or maintenance as therapeutic targets for huntington's disease using induced pluripotent stem cells
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Mechanism of dna strand-break repair deficiency in huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Mechanism of modulation of huntingtin exon 1 aggregation by profilin
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Rhes-sumo circuitry in huntington's disease pathogenesis
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Structure of triplet repeat mrna in neurodegenerative disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
The regulation of synaptic connectivity and homeostasis by huntingtin
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Crmp2; mitochondria; and huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Control of excitatory synapse formation by huntingtin
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Determinants of cell type-specific vulnerability in huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disorders
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Improved monitoring of premanifest and early huntingtons using 7t multimodal mri
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Mitochondrial fragmentation and neurodegeneration in huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Mscs engineered to produce brain-derived neurotrophic factor for the treatment of huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
N-terminal huntingtin and huntington disease neuropathology
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Phosphoinositide signaling: novel potential targets for huntington disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Rare variant whole genome analysis and ipsc validation of putative genetic modifiers of huntington disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Statistical disease modeling and clinimetrics to prepare for preventive trials in huntington disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Endogenous regulation of huntingtin expression as a therapeutic target for huntington's disease
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Validation of Novel Pathogenic Post-Translational Modifications of Huntingtin, and of Modifying Enzymes as Therapeutic Targets for Huntington's Disease
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Avon
BRISTOL
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort - UK
Southmead Hospital
North Bristol NHS Trust
VEREINIGTES KONIGREICH
Gwent
CARDIFF
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort - UK
Cardiff School of Biosciences
FINNLAND
Finland
OULU
FINCA mouse as a tool to study mechanisms behind severe fibrosis and neurodegeneration
University of Oulu
Biocenter Oulu
SPANIEN
Asturias
OVIEDO
The emergent pathogenic role for the intermediate CAG repeats in the HTT gene: from the neuropathological evidences to the molecular findings
Fundación para la Investigación Biosanitaria del Principado de Asturias
FINBA: Fundación para la Investigación Biosanitaria del Principado de Asturias
SPANIEN
Cataluńa
BARCELONA
Advanced genomics and lipidomics for identifying novel causes of inherited movement disorders
Instituto de Química Avanzada de Cataluńa
Unidad de Investigación en Moléculas Bioactivas
SPANIEN
Cataluńa
L'HOSPITALET DE LLOBREGAT
Advanced genomics and lipidomics for identifying novel causes of inherited movement disorders
IDIBELL - Instituto de Investigación Biomédica de Bellvitge
Laboratorio de Enfermedades Neurometabólicas
SPANIEN
País Vasco
SAN SEBASTIÁN
Advanced genomics and lipidomics for identifying novel causes of inherited movement disorders
Instituto de Investigación Sanitaria Biodonostia
Área de Neurociencias
FRANKREICH
ILE-DE-FRANCE
PARIS
Neuroglobin gene overexpression: a promising tool for treating a large spectrum of neurological disorders thanks to its ability to safely and sustainably preserve mitochondrial integrity
Institut National de la Santé et de la Recherche Médicale
ITALIEN
LAZIO
ROMA
Diverse rare diseases caused by functional dysregulation of Rho GTPase-related proteins
ISS - Istituto Superiore di Sanitŕ
Centro Nazionale Malattie Rare
SPANIEN
Cataluńa
BARCELONA
Igenco: In-Depth genomics and cross-omics analysis for undiagnosed rare diseases on a user-friendly collaborative platform
Centro de Regulación Genómica
Centro Nacional de Análisis Genómico
SPANIEN
Cataluńa
BARCELONA
Igenco: In-Depth genomics and cross-omics analysis for undiagnosed rare diseases on a user-friendly collaborative platform
ISGlobal - Instituto de Salud Global de Barcelona
Programa de investigación en Enfermedades no transmisibles y medio ambiente
FINNLAND
Finland
OULU
Novel Diagnostics and Treatment Strategies for Developmental Disorders, Childhood Epilepsies and Movement Disorders
University of Oulu
Biocenter Oulu
KANADA
Colombie-Britannique
VICTORIA
Silent Genomes: Reducing health care disparities and improving diagnostic success for children with genetic diseases from Indigenous populations
University of Victoria
Community Genetics Research Program/Island Medical Program
KANADA
Ontario
TORONTO
Beyond the Genome: Transcriptome Based Diagnostics for Rare Diseases and Cancer
Hospital for Sick Children, Research Institute
SPANIEN
Andalucía
SEVILLA
Development of bioinformatic tools for the automatic handling of secondary findings and their use in genetic and pharmacogenetic counseling
Fundación Progreso y Salud
Área de bioinformática clínica
SPANIEN
Cataluńa
BARCELONA
Catalan Interhospital Network of Genetic Variants to improve genetic diagnosis in rare diseases
Centro de Regulación Genómica
Archivo europeo de genomas y fenomas del CRG
SPANIEN
Cataluńa
BARCELONA
Catalan Interhospital Network of Genetic Variants to improve genetic diagnosis in rare diseases
Hospital Clínic de Barcelona
Servicio de Inmunologia
SPANIEN
Cataluńa
BARCELONA
Catalan Interhospital Network of Genetic Variants to improve genetic diagnosis in rare diseases
Hospital Universitari Vall d'Hebron
Laboratorio de Genética
SPANIEN
Cataluńa
BARCELONA
Catalan Interhospital Network of Genetic Variants to improve genetic diagnosis in rare diseases
Hospital de la Santa Creu i Sant Pau
Servicio de Genética
SPANIEN
Cataluńa
ESPLUGUES DE LLOBREGAT
Federated network for functional genomics of undiagnosed and rare diseases, RareFunction
Fundació Sant Joan de Déu - Institut de Recerca Sant Joan de Déu
Grupo de investigación en Neurogenética y Medicina Molecular
SPANIEN
Cataluńa
ESPLUGUES DE LLOBREGAT
Catalan Interhospital Network of Genetic Variants to improve genetic diagnosis in rare diseases
Hospital Sant Joan de Déu Barcelona
Servicio de Laboratorio
SPANIEN
Cataluńa
L'HOSPITALET DE LLOBREGAT
Catalan Interhospital Network of Genetic Variants to improve genetic diagnosis in rare diseases
Hospital Universitari de Bellvitge
Unidad de Genética Molecular
SPANIEN
Comunidad Valenciana
VALENCIA
Clinical studies, genetic basis and prognosis biomarkers in rare neurodegenerative diseases
Centro de Investigación Príncipe Felipe (CIPF)
CIPF: Centro de Investigación Príncipe Felipe
SPANIEN
Madrid
MADRID
Identification of new genes causing rare diseases in pediatric patients, searching of genetic pharmacological targets, and drugs discovery, the steps for a personalized medicine
Instituto de Investigación Hospital 12 de Octubre
Grupo de investigación en enfermedades raras, mitocondriales y neuromusculares
Multizentrische Forschungsprojekte
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Universitäts- und Rehabilitationskliniken Ulm (RKU)
- Zentrale Koordination des Europäischen HD Netzwerks
- Zentrum für Seltene Erkrankungen am Universitätsklinikum Ulm
- Zentrum für Seltene Erkrankungen (ZSE) ULM
- Ruhr-Universität Bochum
- Humangenetik Bochum
- Centre de Recherche en Cancérologie de Marseille
- Télomčres et Chromatine
- Parc scientifique et technologiques de Luminy
- Trophos SA
- Universitŕ degli Studi di Milano - Scienze Farmacologiche e Biomolecolari
- Laboratorio di Biologia delle Cellule Staminali
- SIENA BIOTECH SPA
- SIENA BIOTECH SPA
- Unitŕ di Neurobiologia
- John van Geest Centre for Brain Repair
- NeuroNE
- Cardiff School of Biosciences
- Alzheimer Europe Office
- Max-Planck-Institut für Multidisziplinäre Naturwissenschaften
- Abteilung Molekulare Neurobiologie
- Azienda Ospedaliera di Padova
- Clinica Pediatrica
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
RATSTREAM: European project on the characterisation of transgenic rat models for neurodegenerative and psychiatric diseases: Automated home cage analyses, live imaging and treatment (FINISHED)
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
NEUROMODEL: Akademisch-industrielles Austausch- und Trainings-Netzwerk zur Erforschung neuer Therapieansätze für die Behandlung von Morbus Huntington
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
TreatPolyQ: Industrial Academic Initial Training Network (Itn) Towards Treatment Of Polyglutamine Diseases -terminated-
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
PhenoRat: European Industrial Doctorate on the generation, characterisation and validation of transgenic rat models of two neurodegenerative diseases: Huntington's disease and spinocerebellar ataxia type 17
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
Neuromics: Integrated European -omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases
DEUTSCHLAND
Baden-Württemberg
ULM
EHDN: Europäisches Huntington Netzwerk
DEUTSCHLAND
Baden-Württemberg
ULM
Enroll-HD: Eine prospektive Registrierungsstudie in einer globalen Huntington-Kohorte
DEUTSCHLAND
Nordrhein-Westfalen
BOCHUM
TreatPolyQ: Allel-spezifische Reduzierung der mutierten Polyglutamin-Proteine zur Behandlung der Huntington-Krankheit, spinozerebellären Ataxie Typ 3 und spinozerebellären Ataxie Typ 7
FRANKREICH
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
REPETOMICS: Genomic Instability of Expanded Repeats in HD and ALS/FTD
FRANKREICH
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
MITOTARGET: mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics
ITALIEN
LOMBARDIA
MILANO
NEuroStemCell: European Consortium for Stem Cell Therapy for Neurodegenerative Diseases (TERMINATED)
ITALIEN
TOSCANA
SIENA
PADDINGTON: pharmacodynamic approaches to demonstration of disease-modification in Huntington's disease by SEN0014196 (TERMINATED)
ITALIEN
TOSCANA
SIENA
TAMAHUD: identification of early disease markers, novel pharmacologically tractable targets and small molecule phenotypic modulators in Huntington's Disease
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
EUNEURONE: European Consortium for Research in Neurodegenerative Diseases
VEREINIGTES KONIGREICH
Gwent
CARDIFF
REPAIR-HD: Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington's disease
LUXEMBURG
LUXEMBOURG
LUXEMBOURG
Alzheimer Europe: European database on rare forms of dementia
DEUTSCHLAND
Niedersachsen
GÖTTINGEN
EUROSPIN: European consortium on synaptic protein networks in Neurological and Psychiatric diseases
ITALIEN
VENETO
PADOVA